As of November 6, 2026, Allogene Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 28, 2026 to September 2, 2026 (Form 8-K, September 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Allogene Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Allogene Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-28 to 2026-09-02. Every row below is cited to the filing it comes from, and this page adds each new change as Allogene Therapeutics, Inc. files it.
Also on the record for Allogene Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.7% of the class | 5%+ stakes | Source |
| September 30, 2026 | Stake report, Schedule 13D/A, by TPG GP A, LLC | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 5.6% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.5% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G/A, by Arie Belldegrun, M.D. | 3.9% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Kenneth Griffin | 2.8% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Lynx1 Capital Management LP | — | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by Arie Belldegrun, M.D. | 5.4% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13G/A, by David D. Chang, M.D., Ph.D. | 4.9% of the class | 5%+ stakes | Source |
| April 23, 2026 | Stake report, Schedule 13G, by Frazier Life Sciences Public Fund, L.P. | 4.7% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Arie Belldegrun, M.D. | 5.8% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13D/A, by Pfizer Inc. | 9% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Allogene Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Allogene Therapeutics, Inc. and the records around it.
Allogene Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Pfizer Inc. also filed stake reports on 4 other companies: TREX BIO, INC. (Oct 2026), ORIC Pharmaceuticals, Inc. (May 2026), NEXTCURE, INC. (Feb 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
- TPG GP A, LLC also filed stake reports on 15 other companies: TPG Inc. (Aug 2026), Ceribell, Inc. (Aug 2026), LifeStance Health Group, Inc. (Aug 2026)
Watch Allogene Therapeutics, Inc.
Get an email when Allogene Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Allogene Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Allogene Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Allogene Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 19 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-02 | Reported | not named in the filing | 8-K, 2026-09-02 | ||
| 2026-05-28 | Reported | not named in the filing | 8-K, 2026-05-28 |
New leaders reset buying decisions — get the Full Report on Allogene Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Allogene Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Allogene Therapeutics, Inc.Every change, in the filing's words
Reported
(b) On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the "Company"), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.
Reported
On May 28, 2026, the Board of Directors (the "Board") of Allogene Therapeutics, Inc. (the "Company"), upon the recommendation of its Nominating and Corporate Governance Committee, approved the appointment of Zachary Roberts, M.D., Ph.D. as the Company's President and Chief Executive Officer, replacing David Chang, M.D., Ph.D. in such capacities.
- The appointment of Dr. Roberts to these positions will become effective July 1, 2026 (the "Effective Date"), and Dr. Chang's last day of service in these positions will be June 30, 2026.
- Effective on the Effective Date, Dr. Roberts was also appointed to the Board as a Class I director, to serve until the Company's 2028 annual meeting of the stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.
- Dr. Roberts currently serves as the Company's Executive Vice President, Research and Development, and Chief Medical Officer and will continue serving as the Company's Chief Medical Officer on an interim basis following the Effective Date.
- In connection with the conclusion of his service as the Company's President and Chief Executive Officer, Dr. Chang will be eligible for certain severance benefits under the terms of the Company's Change in Control and Severance Benefit Plan (the "Severance Plan") as described under "Executive Compensation - Potential Payments and Benefits Upon Termination or Change in Control" in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 30, 2026 (the "Proxy Statement").
Tools for this story
Each opens in a new tab, filled in for Allogene Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.